Analytical Data
-
Gene name
PD1
- Application
-
Alternative Names
PD1；PD1；Programmed cell death Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15116
-
Expression Region
25-167aa
-
AA Sequence
LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSN QTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCG AISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of PD-1 (programmed cell death protein 1) recombinant protein has gained significant attention in recent years, primarily due to its pivotal role in regulating immune responses and its implications in cancer immunotherapy. PD-1 is an inhibitory receptor expressed on T cells and other immune cells, which, upon binding to its ligands PD-L1 and PD-L2, downregulates immune activation and promotes self-tolerance, thereby preventing autoimmunity. However, many tumors exploit this pathway to evade immune surveillance, leading to the development of PD-1/PD-L1 inhibitors as a therapeutic strategy. The production of recombinant PD-1 proteins facilitates a deeper understanding of its structure, function, and interactions, which are critical for the design of effective inhibitors. Moreover, studying PD-1 in its recombinant form allows researchers to explore potential biomarkers for patient selection and treatment responses. As the field of immunotherapy evolves, recombinant PD-1 proteins are being utilized in various applications, including vaccine development, diagnostic assays, and as a basis for engineered immune cells. Overall, research on PD-1 recombinant proteins is central to advancing therapeutic strategies that enhance anti-tumor immunity and improve outcomes for cancer patients.
